The US. Food and Drug Administration (FDA) has approved the drug Nerlynx (neratinib) to help prevent HER2-positive breast cancer recurrence. According to the FDA news release, Nerlynx was administered to more than 2,800 early-stage HER2-positive breast cancer patients over a 2-year clinical trial. Results showed that "after 2 years, 94.2% of users hadn't had their cancer recur, compared with 91.9% of those treated with an inactive placebo.
To read more about this news release, click here.
No comments:
Post a Comment